Effect of Lisinopril Treatment on Genotoxicity of L-Asparaginase (ASNase) in Bone Marrow Stem Cells for Aculte Lymphoblstic Leukemia (ALL)

Abstract

Ibrahim Abdelrahim Ibrahim Humaida

Background: Lisinopril is a drug used to lower blood pressure by blocking the angiotensin-converting enzyme (ACE). It measures the response of myeloid inflammation to bone marrow stem cells. L-asparaginase is a chemotherapeutic agent used to treat acute lymphoblastic leukemia (ALL) by increasing the genotoxicity of bone marrow stem cells. The purpose of this study was to find out the effect of Lisinopril on the genotoxicity of L-asparaginase (ASNase) in bone marrow cells. Materials and Methods: 60 Syrian hamster males’ are divided into three groups. The first group was treated with Lisinopril 10 mg / kg / day for 14 days. The second group was injected with L-asparaginase 3000 IU / kg. The third group was treated with Lisinopril for 14 days following the intraperitoneal injection of L-asparaginase (ASNase) at the end of day 13. Genotoxicity was assessed by calculating the micronucleus (MN) percentage and the mitotic index (MI). Results and Discussions: ASNase significantly increased genotoxicity by increasing% MN and lowering MI. When lisinopril was taken at 10 mg / kg / day, no significant effect was observed. However, a significant decrease in genotoxic effects was observed when mice received Lisinopril injected with 3000 IU / kg ASNase compared with the group treated with ASNase only. This result is shown by reducing% MN and increasing MI. Conclusion: The use of Lisinopril in the treatment of high blood pressure and its cancer treatment agent, L-asparaginase, was found to lower its genotoxicity in bone marrow cells.

PDF